The successful use of rituximab in the setting of drug-induced vasculitis with renal impairment has been reported in several publications [33–36], including reports by Florez et al. and Funada et al. who described cases of ANCA-associated glomerulonephritis induced by an anti-TNF agent (etanercept and certolizumab pegol, respectively) treated with rituximab with a sustained response [33, 34]. This evidence concerns the gene TNF and vasculitis.